Virtus ETF Advisers’s Blueprint Medicines BPMC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-3,777
| Closed | -$329K | – | 478 |
|
|
2024
Q4 | $329K | Buy |
3,777
+681
| +22% | +$62.4K | 0.13% | 231 |
|
|
2024
Q3 | $286K | Hold |
3,096
| – | – | 0.13% | 232 |
|
|
2024
Q2 | $334K | Sell |
3,096
-1,450
| -32% | -$145K | 0.16% | 207 |
|
|
2024
Q1 | $431K | Buy |
4,546
+654
| +17% | +$56.1K | 0.23% | 188 |
|
|
2023
Q4 | $359K | Sell |
3,892
-1,287
| -25% | -$83.4K | 0.23% | 182 |
|
|
2023
Q3 | $260K | Sell |
5,179
-669
| -11% | -$35.7K | 0.16% | 222 |
|
|
2023
Q2 | $370K | Sell |
5,848
-745
| -11% | -$40.5K | 0.22% | 143 |
|
|
2023
Q1 | $297K | Buy |
6,593
+119
| +2% | +$5.36K | 0.16% | 220 |
|
|
2022
Q4 | $284K | Buy |
6,474
+1,309
| +25% | +$62.8K | 0.15% | 292 |
|
|
2022
Q3 | $340K | Buy |
5,165
+76
| +1% | +$4.88K | 0.14% | 258 |
|
|
2022
Q2 | $257K | Buy |
5,089
+1,327
| +35% | +$77.7K | 0.1% | 291 |
|
|
2022
Q1 | $240K | Hold |
3,762
| – | – | 0.11% | 187 |
|
|
2021
Q4 | $403K | Sell |
3,762
-1,540
| -29% | -$161K | 0.15% | 144 |
|
|
2021
Q3 | $545K | Sell |
5,302
-484
| -8% | -$45.1K | 0.24% | 125 |
|
|
2021
Q2 | $509K | Buy |
5,786
+452
| +8% | +$41.4K | 0.21% | 140 |
|
|
2021
Q1 | $519K | Buy |
5,334
+146
| +3% | +$14.6K | 0.22% | 143 |
|
|
2020
Q4 | $582K | Sell |
5,188
-3,174
| -38% | -$334K | 0.24% | 124 |
|
|
2020
Q3 | $775K | Buy |
8,362
+704
| +9% | +$54.2K | 0.41% | 94 |
|
|
2020
Q2 | $597K | Buy |
7,658
+2,822
| +58% | +$191K | 0.28% | 120 |
|
|
2020
Q1 | $283K | Sell |
4,836
-704
| -13% | -$45.3K | 0.12% | 232 |
|
|
2019
Q4 | $444K | Buy |
5,540
+2,744
| +98% | +$205K | 0.07% | 224 |
|
|
2019
Q3 | $205K | Sell |
2,796
-155
| -5% | -$13.4K | 0.04% | 248 |
|
|
2019
Q2 | $278K | Sell |
2,951
-1,790
| -38% | -$148K | 0.06% | 251 |
|
|
2019
Q1 | $380K | Sell |
4,741
-623
| -12% | -$46K | 0.81% | 39 |
|
|
2018
Q4 | $289K | Sell |
5,364
-956
| -15% | -$58.1K | 0.05% | 123 |
|
|
2018
Q3 | $493K | Sell |
6,320
-4,520
| -42% | -$314K | 0.05% | 126 |
|
|
2018
Q2 | $688K | Buy |
10,840
+811
| +8% | +$64.5K | 0.61% | 105 |
|
|
2018
Q1 | $920K | Buy |
10,029
+5,418
| +118% | +$467K | 0.8% | 55 |
|
|
2017
Q4 | $348K | Sell |
4,611
-3,884
| -46% | -$273K | 0.44% | 92 |
|
|
2017
Q3 | $592K | Buy |
8,495
+777
| +10% | +$41.5K | 0.08% | 80 |
|
|
2017
Q2 | $391K | Sell |
7,718
-2,972
| -28% | -$126K | 0.06% | 77 |
|
|
2017
Q1 | $427K | Buy |
10,690
+1,025
| +11% | +$36.7K | 0.08% | 112 |
|
|
2016
Q4 | $271K | Sell |
9,665
-3,381
| -26% | -$102K | 0.08% | 120 |
|
|
2016
Q3 | $387K | Hold |
13,046
| – | – | 0.19% | 81 |
|
|
2016
Q2 | $264K | Buy |
13,046
+2,562
| +24% | +$46.6K | 0.2% | 75 |
|
|
2016
Q1 | $189K | Buy |
+10,484
| New | +$182K | 0.26% | 92 |
|
Other funds holding BPMC
ACA
Virtus ETF Advisers's BPMC Position: Q1 2025 in Review
Virtus ETF Advisers sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 3,777 shares — an estimated $329K sold.
Virtus ETF Advisers first reported a position in BPMC in Q1 2016 and held it in 36 quarters. The position peaked at $920K in Q1 2018. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.
- Virtus ETF Advisers reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
- Virtus ETF Advisers sold 3,777 Blueprint Medicines shares in Q1 2025, an estimated $329K.
- Virtus ETF Advisers first reported a position in Blueprint Medicines in Q1 2016 and held it in 36 quarters.
- Virtus ETF Advisers's Blueprint Medicines position peaked at $920K in Q1 2018.
- 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.
Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.